U.S. Markets close in 3 hrs 16 mins

AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9901-0.0999 (-3.2330%)
As of 12:44PM EDT. Market open.
People also watch
ACRXPBMDAEZSANTHCLSN
Full screen
Previous Close3.0900
Open3.0700
Bid2.9800 x 5600
Ask2.9900 x 1800
Day's Range2.9400 - 3.1100
52 Week Range0.5000 - 3.3000
Volume1,821,174
Avg. Volume5,879,840
Market Cap435.5M
Beta1.40
PE Ratio (TTM)-7.87
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cubeyesterday

    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)

  • AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
    Zacks7 days ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

    AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

  • Associated Press8 days ago

    AVEO reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The cancer drug company posted revenue of $351,000 ...